



Curriculum Vitae

Personal information **Carolina Prieto Fernandez**

Work experience

1. Employer: Spanish Agency of Medicines and Medical Devices (AEMPS)
 - Start date: 052023
 - End date:
 - Position: Alternate member of the CHMP
 - Country: Spain
2. Employer: Spanish Agency of Medicines and Medical Devices (AEMPS)
 - Start date: 022021
 - End date: 052023
 - Position: Head of Oncology Area
 - Activities: Participation, among others, in the following regulatory activities: Clinical assessment of new registration applications and variations of human medicines under National and European procedures (centralised, mutual recognition and decentralised procedures) of oncology medicinal products. Scientific advice for medicinal products for human use. Therapeutic positioning reports for medicinal products for human use.
 - Country: Spain
3. Employer: Spanish Agency of Medicines and Medical Devices
 - Start date: 072016
 - End date: 022021
 - Position: Clinical assessor
 - Activities: Clinical assessment of new registration applications and variations of human medicines under National and European procedures (centralised, mutual recognition and decentralised procedures). Scientific advice. Development of therapeutic positioning reports. Main field: oncology.
 - Country: Spain
4. Employer: Complejo Asistencial Universitario de León
 - Start date: 062016
 - End date: 072016
 - Position: Clinical Hospital Pharmacist
 - Activities: Parenteral nutrition Oncology/haematology
 - Country: Spain
5. Employer: Gerencia Regional de Salud _ Castilla y León
 - Start date: 112013
 - End date: 052016
 - Position: Primary Care Pharmacist
 - Activities: Rational use of medicines.
 - Country: Spain
6. Employer: Complejo Asistencial Universitario de León
 - Start date: 052009
 - End date: 052013
 - Position: Hospital Pharmacist Resident
 - Activities: Pharmaceutical care to hospitalised patients and hospital outpatients, clinical oncology/haematology, compounded preparations, parenteral and enteral nutrition pharmacokinetics, pharmacovigilance, clinical trials.
 - Country: Spain

Education and training

1. Subject: International University Menéndez Pelayo
 - Start date: 2020
 - End date: 2021
 - Qualification: Postgraduate Master on Cancer Immunotherapy
 - Organisation:
 - Country: Spain
2. Subject: National School of Public Health. Institute of Health Sciences of Castilla y León
 - Start date: 2015
 - End date: 2015
 - Qualification: Postgraduate Diploma in Public Health
 - Organisation:
 - Country: Spain
3. Subject: University Autònoma of Barcelona
 - Start date: 2012
 - End date: 2015
 - Qualification: Postgraduate Diploma on Statistics in Health Sciences
 - Organisation:
 - Country: Spain
4. Subject: Spanish Ministry of Health
 - Start date: 2009
 - End date: 2013
 - Qualification: Specialist in Hospital Pharmacy
 - Organisation:
 - Country: Spain

5. Subject: University of León
- Start date: 2009
 - End date: 2010
 - Qualification: Postgraduate Master on Innovation in Biomedical and Health Sciences
 - Organisation:
 - Country: Spain
6. Subject: University of Salamanca
- Start date: 2002
 - End date: 2007
 - Qualification: BSc in Pharmacy
 - Organisation:
 - Country: Spain

Additional information

Publications

Delgado J, Josephson F, Camarero J, García_Ochoa B, López_Anglada L, Prieto Fernández C, Van Hennik PB, Papadouli I, Gisselbrecht C, Enzmann H, Pignatti F. EMA Review of acalabrutinib for the treatment of adult patients with chronic lymphocytic leukemia. *Oncologist* 2021 Mar;26(3):242–249. *Oncologist*. Tzoganis K, Penttilä K, Lähteenvuori J, Lapveteläinen T, López_Anglada L, Prieto C, García_Ochoa B, Enzmann H, Gisselbrecht C, Delgado J, Pignatti F. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma. *Oncologist*. 2021 Jan;26(1):70–76. Michaleas S, Penninga E, Hovgaard D, Dalseg AM, Rosso A, Sarac SB, Jimenez JC, Fernández LL, Fernández CP, Mangas_SanJuan V, Garcia I, Payares_Herrera C, Sancho_López A, Enzmann H, de Castro Lopes Silva MSS, Duarte S, Pignatti F. EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma. *Oncologist*. 2020 Dec;25(12):1067–1074. Ortega_Valín L, Mayorga_Bajo I, Prieto_Fernández C, Del Pozo_Ruiz J, Gutiérrez_Gutiérrez E, Pérez_Sandoval T. Long-term changes in the quality of life of patients with rheumatoid arthritis treated with biological therapies. *Reumatol Clin (Engl Ed)*. 2018 Jul_Aug;14(4):191–195.

Projects

Memberships

Member of the Spanish Society of Hospital Pharmacy (SEFH).

Member of the Oncology European Specialised Expert Community (ESEC)

Other Relevant Information

Courses in oncology, pharmacokinetics, biosimilars, clinical statistics. Speaker in courses of regulatory affairs.